Distinct high-affinity binding sites for benzomorphan drugs and enkephalin in a neuroblastoma--brain hybrid cell line.
- 1 July 1981
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 78 (7) , 4309-4313
- https://doi.org/10.1073/pnas.78.7.4309
Abstract
The high-affinity binding of benzomorphan drugs (ethylketocyclazocine and N-allylnorcyclazocine) and [DAla2,DLeu5] enkephalin was examined in a mouse neuroblastoma--Chinese hamster brain clonal hybrid cell line (NCB-20). Scatchard analysis of saturation binding isotherms indicated the presence of a single binding site for 3H-labeled [DAla2,DLeu5]enkephalin (Kd = 3 nM) and multiple binding sites for [3H]ethylketocyclazocine (Kd = 4 and 20 nM) and N-[3H]allylnorcyclazocine (Kd = 0.5 and 15 nM). Both ethylketocyclazocine and N-allylnorcyclazocine competed (Ki = 10 and 30 nM, respectively) with [3H][DAla2,DLeu5]enkephalin binding in NCB-20 cells but neither [DAla2,DLeu5]enkephalin nor morphine could completely inhibit the specific binding of [3H]ethylketocyclazocine (7 nM) or N-[3H]allylnorcyclazocine (3 nM). Furthermore, not all benzomorphan drugs (e.g., ethylketocyclazocine) were totally efficacious in displacing 3 nM N-[3H]allylnorcyclazocine binding in the presence or absence of high concentrations of [DAla2,DLeu5]enkephalin. The data presented suggest that benzomorphan drugs interact with three distinct high-affinity binding sites: (i) a site that binds enkephalin and morphine in addition to ethylketocyclazocine and N-allylnorcyclazocine; (ii) a site that binds both ethylketocyclazocine and N-allylnorcyclazocine but not enkephalin and morphine; and (iii) a site that binds N-allylnorcyclazocine but not enkephalin, morphine, or ethylketocyclazocine. The first of these sites was comparable to the delta opiate receptor expressed in NG108-15 and N4TG1 cell lines based on the potency series obtained for various opiates and benzomorphan drugs in competition studies with [3H][DAla2,DLeu5]-enkephalin. However, the specific high-affinity benzomorphan binding sites thus far are unique and may represent biochemical correlates of kappa and sigma opiate receptors which have been proposed to exist on the basis of physiological studies.This publication has 17 references indexed in Scilit:
- Discriminative stimulus effects of prototype opiate receptor agonists in monkeysEuropean Journal of Pharmacology, 1980
- Characterization of opioid receptors in nervous tissueProceedings of the Royal Society of London. B. Biological Sciences, 1980
- Bremazocine: A potent, long-acting opiate kappa-agonistLife Sciences, 1980
- Possible role of distinct morphine and enkephalin receptors in mediating actins of benzomorphan drugs (putative kappa and sigma agonists).Proceedings of the National Academy of Sciences, 1980
- Multiple opiate receptors: [3H]ethylketocyclazocine receptor binding and ketocyclazocine analgesia.Proceedings of the National Academy of Sciences, 1980
- Specific protection of the binding sites of D-Ala 2 -D-Leu 5 - enkephalin (δ-receptors) and dihydromorphine (μ-receptors)Proceedings of the Royal Society of London. B. Biological Sciences, 1979
- Endogenous opioid peptides: multiple agonists and receptorsNature, 1977
- A Neuroblastoma × Glioma Hybrid Cell Line with Morphine ReceptorsProceedings of the National Academy of Sciences, 1974
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973